Dogwood Secures Worldwide, Royalty-Free SP16 License—A Strategic Leap for Pain Management

NCI-Funded Phase 1b SP16 Trial Signals Industry Validation

Dogwood Therapeutics (NASDAQ: DWTX) has made a notable strategic move, securing a global, royalty-free license to develop and commercialize SP16, a novel intravenous therapy aimed at addressing cancer-related pain, particularly chemotherapy-induced peripheral neuropathy (CIPN). Uniquely, this phase 1b study is fully funded by the National Cancer Institute (NCI), underlining both scientific interest and the large unmet need for new solutions in this space.

With projected patient enrollment set for the first half of 2026, SP16 positions Dogwood as a leading developer of innovative, non-opioid therapies for pain and neuropathy. This development also aligns with Dogwood's objective to maximize value for shareholders without additional near-term capital allocation to this trial.

SP16’s Mechanism: Synergy Potential with Halneuron®

SP16 is a first-in-class LRP1 agonist discovered by Serpin Pharma. In preclinical studies, SP16 has shown both anti-inflammatory and neural repair effects. These properties hold promise for managing the difficult-to-treat symptoms of CIPN—a side effect experienced by many cancer patients receiving chemotherapy. This approach may work synergistically with Halneuron®, Dogwood's NaV1.7 inhibitor, which is currently in a Phase 2b trial and has shown significant pain reduction in previous studies.

Both agents offer differentiated mechanisms and potential complementary benefits, expanding Dogwood’s pipeline with “shots on goal” in a high-value therapeutic space. Notably, the National Cancer Institute’s direct investment into SP16’s clinical development underscores its potential and helps Dogwood manage financial risk as the program advances.

Deal Structure: All-Stock Transaction Broadens Dogwood’s Ownership Base

^*Rounded to the nearest hundredth.

The deal sees Serpin Pharma receiving 382,034 shares of Dogwood common stock and 179.19 shares of a new series of non-voting convertible preferred stock (with a 1:10,000 conversion ratio), totaling 7.31% ownership on a fully diluted basis, subject to regulatory approvals. The transaction structure ties Serpin’s incentives to Dogwood’s long-term success, ensuring strategic alignment.

Pipeline: Two Distinct Platforms Addressing Unmet Needs

Dogwood’s research pipeline is now built around two non-opioid mechanisms: SP16 for anti-inflammatory/neural repair, and Halneuron® for sodium channel inhibition. Halneuron®, Dogwood’s lead candidate, is progressing through a Phase 2b trial for CIPN with interim data anticipated by December 2025. Both candidates target major pain conditions often underserved by existing therapies and both may ultimately address a spectrum of symptoms, including those beyond pain.

Key Takeaway: Strengthened Pipeline and Industry Endorsement Set Dogwood Apart

This licensing move not only deepens Dogwood’s portfolio in pain management but also reflects confidence from external stakeholders such as the NCI. The fully funded SP16 study enables Dogwood to progress its pipeline without additional financial risk, a rarity among small- and mid-cap biotechs.

With multiple clinical shots at transformative pain solutions, Dogwood’s expanding non-opioid platform and its novel, royalty-free SP16 license put the company in a stronger competitive position heading into 2026. Investors and industry observers may want to follow upcoming milestones—especially the interim Halneuron® data expected by the end of 2025 and enrollment in the SP16 trial soon after.

Webcast and Additional Resources

Dogwood will host a webcast today, September 29, 2025, at 8:30 a.m. Eastern Time. Investors can dial in at 888-506-0062 (US) or 973-528-0011 (International), with access code 793917. More information and the webcast replay will be available on the company’s investor relations page.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI